Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Psilocybin Scheduling topic
No spam. Unsubscribe anytime.
Committee reports bill to conform state law to federal psilocybin scheduling
Summary
Senators discussed House Bill 563, which would make state law conform to future federal scheduling of psilocybin (including potential clinical indications such as treatment-resistant depression); Senator Black signaled likely amendments and the bill was reported out of committee.
The committee considered House Bill 563, which would cause Mississippi law to conform to any federal scheduling of psilocybin until the next legislative session, and reported the bill out of committee.
Chair described psilocybin as a mushroom-derived compound undergoing clinical trials for treatment‑resistant depression and said the bill would "conform to that scheduling until the convening of the next legislative session." Senator Black said, "Based on the makeup of the committee right now, I'm pretty tempted to make several amendments," and noted the clinical trials were making "great progress." Committee members discussed whether scheduling would apply only to treatment‑resistant depression; the Chair and members named additional indications mentioned in the transcript, including traumatic brain injury and substance use disorder. A member asked whether adding a drug to the schedule would automatically instruct prescribers on conditions to treat; the Chair replied providers would need to follow treatment recommendations and that scheduling itself does not prescribe a single use.
The Chair called for motions that the title was sufficient and recorded that "That bill will be reported." The transcript contains no roll‑call tally for the motions or recorded vote counts.
